Spanish pharmaceutical companies have developed a strong strategy in the last years to expand their products around the world, but these processes do not finish in selling drugs abroad, reports The Pharma Letter’s correspondent in Spain.
Also, almost every one of them has opened up new affiliates, commercial offices and production or R&D sites in other countries. In this sense, the favorite places were European countries, the USA or others regions, such as Latin America or Asia, for instance.
With regard to global presence, it is right to highlight Grifols (GRLS: MC), with 24 affiliates in Europe, North America, South America, Asia Pacific and Southeast Asia. Also, the Barcelona-based company has industrial facilities in the USA (Clayton, North Carolina; Melville, New York; and Los Angeles, California), Mexico (Guadalajara), Switzerland (Dudinguen), and Australia (Melbourne). People from the company declined to make statements about their plans for the future.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze